Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Aug 2025
Gastric cancer is one of the leading causes of cancer-related mortality worldwide, and peritoneal metastasis, wherein the cancer spreads to the peritoneum or the lining of the abdominal cavity, represents the most common ...
Read Full NewsFor patients with high-risk muscle-invasive bladder cancer, adjuvant radiotherapy improves disease control without increasing the risk of serious side effects.
Results pinpoint who has the worst prognosis and might benefit from different therapies.
1.
BMI is linked to heart damage from chemotherapy in breast cancer patients.
2.
FDA Advisors Split on Regimens for Breast, Prostate Cancers
3.
What are the factors that cause oral mucositis to be severe after receiving radiation for head and neck cancer?
4.
'Chemo brain' cognitive issues linked to poor lymphatic-system drainage
5.
Brain cancer: a Q&A session.
1.
Unlocking the Benefits of Cyramza: A New Frontier in Cancer Treatment
2.
Beyond Symptoms: The Predictive Promise of Targeted Radionuclide Therapy in Palliative Oncology
3.
Understanding Melanoma: From Diagnosis to Healing and Excision in Denver
4.
Exploring the Causes and Treatments of Thrombocytopenia: A Comprehensive Guide
5.
Pharmacological Frontier of Precision Oncology, Immunotherapies, and the Evolving Art of Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
2.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
3.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
4.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
5.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge